☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Non-Metastatic Castration-Resistant Prostate Cancer
Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer
March 31, 2020
Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostat...
February 12, 2020
Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
February 15, 2019
Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)
February 14, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.